GE HealthCare Trial Seeks Manganese MRI Edge With Valuation Upside

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...

GE HealthCare (GEHC) Begins Phase 2/3 Trial for Innovative MRI Contrast Agent

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.

First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...
Yahoo

Scientists Discover How Much Toxic Metal Used in MRI Scans Invades Human Tissue

Add Yahoo as a preferred source to see more of our stories on Google. A magnetic resonance imaging (MRI) scan is an important tool to help doctors see what’s happening inside your body. But new, ...
Business Wire

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Nanowerk

How magnetic interactions between neighboring nanoparticles influence MRI contrast

Precisely tuning the spacing between iron oxide nanoparticles optimizes their magnetic interactions to enhance MRI contrast, offering a simpler path to better imaging agents. (Nanowerk News) Magnetic ...